Vaxdyn
Vaxdyn develops vaccines against antimicrobial-resistant bacteria, including its lead candidate K-VAX for Klebsiella pneumoniae and Acinetobacter baumannii.
€11MSeries A
LeadBC
Biovance Capital
Activity from announced rounds
Activity in this selectionOct 16, 2026 · Jul 19, 2026
- Rounds participated in
- 1
- Confirmed lead rounds
- 1 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $12.8M 1 disclosed · full round size, not this investor’s share